ライフサイエンスコーパス: vascular remodeling

1 transcriptional network underlying lymphatic vascular remodeling.

2 Rbeta) known to be important in pathological vascular remodeling.

3 PMFs are key cells in hepatic vascular remodeling.

4 characterized by cellular proliferation and vascular remodeling.

5 urface thiol-redox control of thrombosis and vascular remodeling.

6 e cells (SMC) is a key culprit of pathologic vascular remodeling.

7 mokine receptor CXCR7 in atherosclerosis and vascular remodeling.

8 e stress promote ROS1 activation and mediate vascular remodeling.

9 ysfunction, smooth muscle contractility, and vascular remodeling.

10 er, this strategy is limited by pathological vascular remodeling.

11 liferation, a major contributor to pulmonary vascular remodeling.

12 lopment of a functional microvasculature and vascular remodeling.

13 beyond BAS to other vasculopathies involving vascular remodeling.

14 ma formation but not for hypertension-driven vascular remodeling.

15 ignaling and then contribute to veins during vascular remodeling.

16 ased platelet activation, and less pulmonary vascular remodeling.

17 vascular endothelial growth factor-dependent vascular remodeling.

18 ignaling is necessary but not sufficient for vascular remodeling.

19 sociated with several human cancers and with vascular remodeling.

20 imulus for PASMC proliferation and pulmonary vascular remodeling.

21 vasoregulation, hemostasis, thrombosis, and vascular remodeling.

22 ence of histological evidence of accentuated vascular remodeling.

23 critical role of mTOR signaling in pulmonary vascular remodeling.

24 ressive, usually fatal disease with abnormal vascular remodeling.

25 ting angiogenesis, but seems dispensable for vascular remodeling.

26 smooth muscle cells leading to (mal)adaptive vascular remodeling.

27 eatening disease, characterized by pulmonary vascular remodeling.

28 nd ER stress promote proliferative pulmonary vascular remodeling.

29 egions of disturbed flow, and flow-dependent vascular remodeling.

30 es such as inflammation, carcinogenesis, and vascular remodeling.

31 h muscle cell paracrine communication during vascular remodeling.

32 tion of pathologic autoantibodies that drive vascular remodeling.

33 s in blood flow and how such responses drive vascular remodeling.

34 ed contractile gene expression, and abnormal vascular remodeling.

35 lar cells and macrophages is critical during vascular remodeling.

36 pulmonary vascular resistance by attenuating vascular remodeling.

37 AH) is characterized by vasoconstriction and vascular remodeling.

38 RNAs that have been shown to play a role in vascular remodeling.

39 and are associated with increased pulmonary vascular remodeling.

40 induces genes that regulate inflammation and vascular remodeling.

41 ized cardiac output, and decreased pulmonary vascular remodeling.

42 ucing mucus metaplasia, airway fibrosis, and vascular remodeling.

43 eveloping yolk sac vessels to mediate normal vascular remodeling.

44 Current therapies fail to fully reverse this vascular remodeling.

45 th improvement of hemodynamics and pulmonary vascular remodeling.

46 cterized by lung endothelial dysfunction and vascular remodeling.

47 as used to characterize the impact of LG3 on vascular remodeling.

48 ates in the development of PAH and pulmonary vascular remodeling.

49 as important regulators of angiogenesis and vascular remodeling.

50 ance in the arterial wall and contributes to vascular remodeling.

51 ia in addition to basal cell hyperplasia and vascular remodeling.

52 henotypes can be altered during pathological vascular remodeling.

53 in persistent inflammation and pathological vascular remodeling.

54 ipating in pulmonary hypertension-associated vascular remodeling.

55 asoconstriction is correlated with pulmonary vascular remodeling.

56 ion and overactivation of Tie2 can result in vascular remodeling.

57 participant in blood pressure regulation and vascular remodeling.

58 perkinetic circulation, volume overload, and vascular remodeling.

59 CaMKIIdelta promotes VSM proliferation and vascular remodeling.

60 eutic targets for neointima formation during vascular remodeling.

61 by aldosterone may mediate adverse pulmonary vascular remodeling.

62 mpairs re-endothelialization and accelerates vascular remodeling.

63 sclerosis through increased inflammation and vascular remodeling.

64 ibutes to impaired re-endothelialization and vascular remodeling.

65 y for Schistosoma-induced TGF-beta-dependent vascular remodeling.

66 zed by lung endothelial cell dysfunction and vascular remodeling.

67 icroRNA cluster, which is highly involved in vascular remodeling.

68 embryos die at midgestation with defects in vascular remodeling, a process critically influenced by

69 editary hemorrhagic telangiectasia (HHT) and vascular remodeling, acting via the HHT target genes, en

70 Vasoconstrictive and vascular remodeling actions of endothelin (ET) 1 and ang

71 cells as critical adventitial progenitors in vascular remodeling after acute and during chronic injur

72 rotein E knockout mice significantly reduced vascular remodeling after acute induction of disturbed f

73 RB6-8C5 or 1A8 reduced neutrophil influx and vascular remodeling after infection by about 90%.

74 Similarly, vascular remodeling after infection was suppressed in Cx

75 Atherosclerosis and vascular remodeling after injury are driven by inflammat

76 ressing non-classical monocytes that support vascular remodeling after injury.

77 We tested CaMKIIgamma function in vascular remodeling after injury.

78 ng the mechanisms of intimal hyperplasia and vascular remodeling, although their technical complexity

79 n of TIMP3 is critical in preventing adverse vascular remodeling and AAA.

80 stromal microenvironment that contributes to vascular remodeling and aberrant tumor angiogenesis in t

81 ed before triggering to identify plaques and vascular remodeling and after triggering to identify thr

82 D158d-stimulated senescent NK cells promoted vascular remodeling and angiogenesis as assessed by func

83 tory phenotype, and their secretome promotes vascular remodeling and angiogenesis.

84 X2 expression histologically correlates with vascular remodeling and calcification.

85 lungs of patients with PAH, contributing to vascular remodeling and calcium-related biomineralizatio

86 st agent, and T1 mapping were used to assess vascular remodeling and calculate the plaque area and ve

87 cation and paracrine factors could undermine vascular remodeling and cytotrophoblast-induced lymphang

88 us H2S production predisposes the animals to vascular remodeling and early development of atheroscler

89 molecular mechanism that promotes pulmonary vascular remodeling and fibrosis.

90 5-deficient mice, a model that is linked to vascular remodeling and fibrosis.

91 Del-1 plays a regulatory role in vascular remodeling and functions in innate immunity thr

92 n (PAH) is characterized by severe pulmonary vascular remodeling and has long been associated with im

93 somes, have been identified as regulators of vascular remodeling and have promise as therapeutics for

94 The extensive changes in pulmonary vascular remodeling and hemodynamics in response to hypo

95 enic proteins (BMPs) and blood flow regulate vascular remodeling and homeostasis.

96 or genetic removal of the A(2B)R attenuated vascular remodeling and hypertension in our model.

97 tromal cell-derived exosomes (MEX) inhibited vascular remodeling and hypoxic pulmonary hypertension,

98 r eplerenone prevented or reversed pulmonary vascular remodeling and improved cardiopulmonary hemodyn

99 pathway in diseases characterized by adverse vascular remodeling and increased permeability.

100 (RV) hypertrophy and prevented the pulmonary vascular remodeling and increases in PASMC [Ca(2+)](i),

101 MP-9 forms may help explain the constitutive vascular remodeling and infiltrative nature of these les

102 Assessment of pulmonary vascular remodeling and inflammation in 62 PAH and 28 co

103 herein FOXO1-driven ANG2 expression promotes vascular remodeling and leakage.

104 her, the major effects of EVE appeared to be vascular remodeling and maturation of functional blood v

105 gment of perlecan of potential importance in vascular remodeling and neointima formation.

106 ry arterial hypertension is characterized by vascular remodeling and neomuscularization.

107 trols PASMC survival to promote hypertrophic vascular remodeling and PAH.-

108 cally modified mouse model with obliterative vascular remodeling and pathophysiology recapitulating c

109 signaling and reduced established pulmonary vascular remodeling and PH.

110 ved in the immunologic process that triggers vascular remodeling and plaque deposition and is associa

111 iR-210 were detectable in 2 rodent models of vascular remodeling and plaque rupture.

112 r TGFbeta1 signaling and has been studied in vascular remodeling and preeclampsia.

113 Implication of RUNX2 in PAH-related vascular remodeling and presence of calcified lesions in

114 cp2KO mice spontaneously developed pulmonary vascular remodeling and pulmonary hypertension and exhib

115 deletion of HIF-1alpha attenuated pulmonary vascular remodeling and pulmonary hypertension in chroni

116 ha in smooth muscle contributes to pulmonary vascular remodeling and pulmonary hypertension in chroni

117 t EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice a

118 The pulmonary vascular remodeling and pulmonary hypertension were depe

119 soconstriction and chronic hypoxia can cause vascular remodeling and pulmonary hypertension, conflict

120 of autoantibodies into rats caused pulmonary vascular remodeling and pulmonary hypertension.

121 s of self-tolerance contributes to pulmonary vascular remodeling and pulmonary hypertension.

122 rtension (PAH) is characterized by pulmonary vascular remodeling and right heart failure.

123 VIP gene in mice leads to PAH with pulmonary vascular remodeling and right ventricular (RV) dilatatio

124 ti-Gremlin 1 antibody also reduced pulmonary vascular remodeling and right ventricular hypertrophy in

125 poxic/SU5416-dependent increase in pulmonary vascular remodeling and right ventricular hypertrophy.

126 eptor type 2 (BMPR2) signaling, and reversed vascular remodeling and right-heart hypertrophy in vivo.

127 ective contributions to the initial stage of vascular remodeling and sprouting lymphangiogenesis were

128 postnatal retinal vessels leads to aberrant vascular remodeling and sprouting, as well as markedly r

129 ve impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening.

130 ation of SERCA2a is permissive for pulmonary vascular remodeling and the development of PAH.

131 s novel targets, RhoB and MLC2, resulting in vascular remodeling and the development of PAH.

132 creased gremlin in hypoxia-induced pulmonary vascular remodeling and the increased pulmonary vascular

133 Therefore, the reduction of vascular remodeling and the up-regulation of Kallikrein-

134 gh, contribute to lung fibrosis, maladaptive vascular remodeling, and allergic asthma.

135 is characterized by inflammation, pulmonary vascular remodeling, and angio-obliteration leading to e

136 ions in bioavailable nitric oxide, increased vascular remodeling, and associated increases in vascula

137 embryonic organ development, hematopoiesis, vascular remodeling, and atherogenesis.

138 rp5/6 pathway is essential for angiogenesis, vascular remodeling, and barrier maturation, how these d

139 cts of imatinib (100 mg/kg) on hemodynamics, vascular remodeling, and downstream molecular signatures

140 lol in improving cardiac function, pulmonary vascular remodeling, and inflammation of rats with monoc

141 Serum, lung and liver cytokine, pulmonary vascular remodeling, and liver histology were assessed.

142 gen delivery, by regulating angiogenesis and vascular remodeling, and oxygen utilization, by regulati

143 S is associated with plaque burden, positive vascular remodeling, and plaque disruption in a rabbit m

144 m the effects of hypoxia on the right heart, vascular remodeling, and raised serum endothelin 1 level

145 icits pulmonary dilation, prevents pulmonary vascular remodeling, and reduces the right ventricular h

146 ed right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular-arte

147 improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function.

148 eased right ventricular pressures, pulmonary vascular remodeling, and right ventricular hypertrophy.

149 of right ventricular hypertrophy, pulmonary vascular remodeling, and right ventricular systolic pres

150 rized by elevated pulmonary artery pressure, vascular remodeling, and ultimately right ventricular he

151 PH, cardiac function, vascular remodeling, and valve structure were assessed b

152 pmental and tumor angiogenesis, inflammatory vascular remodeling, and vessel leakage.

153 mphysema; mucus metaplasia; airway fibrosis; vascular remodeling; and right ventricle cardiac hypertr

154 is highly active in extracellular matrix and vascular remodeling, angiogenesis, and tumor progression

155 er fibrosis expanding from portal tracts and vascular remodeling are determinant factors in the progr

156 Angiogenesis and vascular remodeling are essential for the establishment

157 Although the cues governing vascular remodeling are not fully understood, target-der

158 inflammation, water and salt retention, and vascular remodeling, are mediated via its type 1 (AT1) r

159 d pericyte coverage contributes to pulmonary vascular remodeling as a source of smooth muscle-like ce

160 erial hypertension (PAH) is characterized by vascular remodeling associated with obliteration of pulm

161 g processes are involved in the inflammatory vascular remodeling associated with the resolution of DV

162 ic arch variations noted during normal rapid vascular remodeling at stage 21 identify a temporal wind

163 ophysiology, with cellular proliferation and vascular remodeling being the key pathogenic events alon

164 ecular explanation behind the alterations in vascular remodeling, biomechanical properties, and aneur

165 actor (VEGF) are both capable of stimulating vascular remodeling, but the resulting blood vessel netw

166 n HF, PH is associated with global pulmonary vascular remodeling, but the severity of PH correlates m

167 , under pathogen-free conditions, ANG2 drove vascular remodeling by acting as an agonist, promoting h

168 A20 protects against pathologic vascular remodeling by inhibiting the inflammatory trans

169 ents with established PAH reverses pulmonary vascular remodeling by reducing proliferation and induci

170 hat PAR-2-dependent signaling contributes to vascular remodeling by various mechanisms.

171 pertension (PAH) is a disease of progressive vascular remodeling, characterized by dysregulated growt

172 The time course of vascular remodeling coincided with the influx of neutrop

173 During vascular remodeling, colocalization of Notch2 and p27(ki

174 -beta in extracellular matrix production and vascular remodeling, coupled with increased TGF-beta exp

175 how that factors found in young blood induce vascular remodeling, culminating in increased neurogenes

176 s from ptges(-/-) mice reduces inflammation, vascular remodeling, cytokine generation, and airway rea

177 th endothelial lined arteries; but exhibited vascular remodeling defects and early lethality.

178 Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with limited therapeutic opt

179 rgic signaling to disturbed vasodilation and vascular remodeling during atherosclerosis progression.

180 of nitrite anion therapy for ischemic tissue vascular remodeling during diabetes remain unknown.

181 ANG2 drove vascular remodeling during Mycoplasma pulmonis infection

182 oup first reported that RGS5 is important in vascular remodeling during tumor angiogenesis.

183 ammation in vessels, leading to pathological vascular remodeling during VZV vasculopathy and persiste

184 owth and angiogenesis and displayed a marked vascular remodeling effect, leading to normalized microv

185 ndent vasorelaxation that is associated with vascular remodeling, endothelial nitric oxide synthase u

186 en the transpulmonary gradient and pulmonary vascular remodeling existed, with numerically stronger a

187 rophoblasts, STBs) and invasion and maternal vascular remodeling (extravillous trophoblasts, EVTs).

188 migration to the perivascular space and that vascular remodeling following arterial occlusion occurs

189 ay act as a risk factor contributing to lung vascular remodeling following endothelial cell injury.

190 signaling is a promising strategy to reverse vascular remodeling for treatment of severe PAH.

191 ntribute to the process of hypoxic pulmonary vascular remodeling; however, the specific role of pulmo

192 lar development and the pathogenic events of vascular remodeling i.e. restenosis.

193 isruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth

194 Despite clinical and histologic vascular remodeling in all patients with PH-COPD and PH-

195 nt of PH, right ventricular hypertrophy, and vascular remodeling in both preclinical models of PH.

196 nsiveness in vitro, and attenuated occlusive vascular remodeling in chronically hypoxic Sugen5416-tre

197 linking hyperglycemia, hypercoagulation, and vascular remodeling in diabetes mellitus.

198 killer T (NKT) cells play a critical role in vascular remodeling in different physiological and patho

199 accumulation of pro-angiogenic monocytes and vascular remodeling in experimental hepatopulmonary synd

200 mproved survival, RV function, and pulmonary vascular remodeling in experimental PH.

201 estrogen metabolites in promoting pulmonary vascular remodeling in familial pulmonary arterial hyper

202 We conclude that the pathogenesis of vascular remodeling in hypoxic PH involves an early comp

203 y pathophysiological components of pulmonary vascular remodeling in idiopathic pulmonary arterial hyp

204 here was a significant increase in pulmonary vascular remodeling in infected mice.

205 Stem cells are thought to enhance vascular remodeling in ischemic tissue in part through p

206 right ventricular hypertrophy and pulmonary vascular remodeling in monocrotaline-exposed rats.

207 inhibitor-1, and mitigated PH and pulmonary vascular remodeling in monocrotaline-treated rats, SU541

208 Increased VEGF expression promoted islet vascular remodeling in NOD mice, and inhibition of VEGFR

209 urvive and proliferate, thus contributing to vascular remodeling in PAH.

210 rm shear profiles that are critical loci for vascular remodeling in PAH.

211 macrophage activation as the sole driver of vascular remodeling in PH, and uncover a cross-talk betw

212 eceptor interaction enable discrimination of vascular remodeling in PH-IPF or PH-COPD.

213 key pathophysiologic components of pulmonary vascular remodeling in pulmonary arterial hypertension (

214 e dysregulation has been linked to occlusive vascular remodeling in pulmonary arterial hypertension (

215 yperaldosteronism correlates positively with vascular remodeling in pulmonary arterial hypertension,

216 h muscle cells (PASMCs) is key to pathologic vascular remodeling in pulmonary hypertension (PH).

217 cellular processes underlying the pulmonary vascular remodeling in pulmonary hypertension and those

218 harmacological approaches to treat pulmonary vascular remodeling in pulmonary hypertension.

219 contribution during chronic hypoxia-induced vascular remodeling in Pw1(nLacZ+/-) mouse expressing be

220 ries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.

221 Adaptive vascular remodeling in response to arterial occlusion ta

222 ng the SMC migration that underlies negative vascular remodeling in response to injury.

223 raphic investigation suggests that pulmonary vascular remodeling in smokers is characterized by dista

224 wth factor (VEGF) plays an important role in vascular remodeling in the asthmatic airways.

225 d pulmonary hypertension and the concomitant vascular remodeling in the lung.

226 ur study identified a novel role of PAR-2 in vascular remodeling in the lung.

227 loid-specific conditional deletion of FAK on vascular remodeling in the mouse femoral arterial ligati

228 16 injection reduced pulmonary pressures and vascular remodeling in the PH-HFpEF model with robust ac

229 is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arteri

230 st agent enables more accurate assessment of vascular remodeling in the prediction of vulnerable plaq

231 termine whether neutrophils are required for vascular remodeling in the respiratory tract by using My

232 erapy effectively stimulates ischemic tissue vascular remodeling in the setting of metabolic dysfunct

233 nstrate that both pulmonary eosinophilia and vascular remodeling in the setting of PGE(2) deficiency

234 sistent with cGMP-elevating agents reversing vascular remodeling in this PAH model.

235 esponses to flow in vitro and flow-dependent vascular remodeling in vivo.

236 t to HSS and if the shear defect partakes in vascular remodeling in vivo.

237 ular pressure and hypertrophy, and pulmonary vascular remodeling in wild-type mice exposed to 3 weeks

238 wn to play an important role in pathological vascular remodeling including atherosclerosis and postan

239 xygenease-activating protein, and markers of vascular remodeling, including PAI-1 and RhoB.

240 VM group) demonstrated significant pulmonary vascular remodeling, including the presence of early and

241 ntaneous severe PAH with extensive pulmonary vascular remodeling, including vascular occlusion and pl

242 or alpha, stimuli implicated in pathological vascular remodeling, increase Adamts-1 expression in end

243 dly expand into primitive plexi that undergo vascular remodeling into circulatory networks, requiring

244 Vascular remodeling is a feature of sustained inflammati

245 Following transplantation, appropriate vascular remodeling is crucial to ensure the survival an

246 Vascular remodeling is essential for tissue repair and i

247 VEGF in modulation of tumor angiogenesis and vascular remodeling is less understood.

248 s-1 upregulation by inducers of pathological vascular remodeling is mediated by specific signal trans

249 This vascular remodeling is reversible, and hydrogen sulfide

250 factor play important roles in angiogenesis, vascular remodeling, local tumor growth, and metastatic

251 oxygen sensing and in pulmonary hypertension vascular remodeling may open a new window in biomarker a

252 This suggests that tumor vascular remodeling may redirect the organism-wide signa

253 essels regress, identifies these proteins as vascular remodeling molecules crucial for angioplasticit

254 tein synthesis, respectively, to promote the vascular remodeling needed for normal vision.

255 isorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, r

256 Vascular remodeling of donor, PH-COPD, and PH-IPF pulmon

257 PDE1 inhibition suppressed vascular remodeling of human saphenous vein explants ex

258 IUGR is associated with vascular remodeling of the stem villus arteries.

259 rombus resolution by increasing inflammatory vascular remodeling of venous thrombi in vivo, and the p

260 estigate the role of the magnitude of ESS on vascular remodeling, plaque burden, and disruption using

261 During this vascular remodeling process, primordial endothelial cell

262 rs involved in both the inflammatory and the vascular remodeling processes.

263 ls involved in both the inflammatory and the vascular remodeling processes.

264 lex yet fascinating interplay with pulmonary vascular remodeling, promising to lead to novel therapeu

265 y pressure, vascular resistance, and limited vascular remodeling quantified by histology.

266 However, the mechanisms of obliterative vascular remodeling remain elusive; hence, current thera

267 gfrbeta, which effect ultimately fosters the vascular remodeling required for normal vision in the mo

268 The vascular remodeling responsible for pulmonary arterial h

269 ERCA2a) decreased pulmonary artery pressure, vascular remodeling, right ventricular hypertrophy, and

270 Pulmonary vascular remodeling severity was associated with reducti

271 al administration of TNFalpha did not induce vascular remodeling similar to that seen in infection.

272 stenosis causes maladaptive ventricular and vascular remodeling that can lead to pulmonary hypertens

273 standing of the regulation of vasomotion and vascular remodeling that have led to "reverse-remodeling

274 ildren conceived by ART manifest cardiac and vascular remodeling that is present in fetal life and pe

275 ole in several biological systems, including vascular remodeling that occurs following percutaneous t

276 ely modulate tumor growth, angiogenesis, and vascular remodeling through a VEGF-dependent mechanism.

277 trix metalloproteinase (MMP)-2, which drives vascular remodeling through degradation of matrix and no

278 sed into the circulation are able to promote vascular remodeling through endothelium activation and i

279 ly modulates tumor growth, angiogenesis, and vascular remodeling through VEGF-dependent spatiotempora

280 activation by chronic hypoxia can accentuate vascular remodeling to promote development of pulmonary

281 increases in WSS are followed by a period of vascular remodeling to restore normative hemodynamic loa

282 cal links between endothelin-1 and pulmonary vascular remodeling, to our knowledge, the association b

283 predisposes to thrombotic and proliferative vascular remodeling, to which thrombin contributes via a

284 possibly contributing to occlusive pulmonary vascular remodeling triggered by EC apoptosis.

285 helps to mediate the restoration of yolk sac vascular remodeling under both conditions.

286 Vascular remodeling under conditions of growth or exerci

287 cate an important role of TRPC1 in pulmonary vascular remodeling underlying the development of hypoxi

288 Vascular remodeling was characterized 4 weeks after femo

289 Vascular remodeling was induced with thalidomide dissolv

290 ith right ventricular dysfunction, pulmonary vascular remodeling was not more severe.

291 ciated pulmonary hypertension, we found that vascular remodeling was not responsible for observed inc

292 damage, microcirculation, regeneration, and vascular remodeling were evaluated at postoperative days

293 lish this, cellular and molecular changes in vascular remodeling were monitored in mice exposed to bl

294 induced pulmonary hypertension and pulmonary vascular remodeling were not or only slightly affected b

295 The hemodynamic and pulmonary vascular remodeling were reversed by iron replacement (f

296 Calcineurin inhibitors induce detrimental vascular remodeling, which may be one cause of chronic a

297 ling in c-KitbetaTg mice induced substantial vascular remodeling, which resulted in increased islet i

298 ular resistance, RV afterload, and pulmonary vascular remodeling, which was associated with reduced l

299 IDD rats exhibited profound pulmonary vascular remodeling with prominent muscularization, medi

300 ng the role of the mTOR pathway in pulmonary vascular remodeling, with a specific focus on the hypoxi